The COUNTER-COVID study: Oral imatinib to reverse pulmonary vascular leak and disease burden in COVID-19
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.043E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20202022Known Financial Commitments (USD)
$546,881.64Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
PendingResearch Location
NetherlandsLead Research Institution
Amsterdam University Medical Center - location VUmcǨǨ ǨResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Project description One in five patients with COVID-19 develops serious lung damage, necessitating hospitalization or even an Intensive Care Unit. This lung damage is caused, among other things, by leakage in the smallest blood vessels of the lung, whereby fluid escapes from the bloodstream and fills the alveoli. The fluid in the alveoli seriously impedes oxygen uptake and causes life-threatening oxygen deficiency. There are currently no medications to prevent leakage of small blood vessels. Research and expected outcomes Previous research in the laboratory has shown that the existing drug imatinib prevents blood vessel leakage. This protective effect of imatinib on the blood vessel wall can therefore potentially be used in patients with COVID-19. The COUNTER-COVID study tests whether patients treated with imatinib recover faster than patients who receive standard care.